The U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to two research projects funded by the California Institute for Regenerative Medicine (CIRM). RMAT is a fast-track designation that can help speed up the development, review, and potential approval of treatments for serious or life-threatening diseases. The first RMAT designation … Continue reading Two CIRM-funded research projects receive RMAT designation from FDA
CIRM News
CIRM Recommendations from Strategic Allocation Framework
The California Institute for Regenerative Medicine (CIRM), one of the world’s largest institutes dedicated to regenerative medicine, announced key recommendations at the September 26, 2024, Independent Citizens’ Oversight Committee Meeting from its Strategic Allocation Framework (SAF), a structured and data-driven effort designed to prioritize resources and maximize the impact of CIRM’s funding. These recommendations mark … Continue reading CIRM Recommendations from Strategic Allocation Framework
CIRM awards $8 million to Support Groundbreaking Gene Therapy for AML and MDS
Image source: Canva Around 20,000 Americans are affected by acute myeloid leukemia (AML) each year. AML is a type of cancer that originates in the bone marrow and rapidly enters the bloodstream. Additionally, many individuals are impacted by myelodysplastic syndromes (MDS), which are blood disorders that result in the improper formation or functioning of blood … Continue reading CIRM awards $8 million to Support Groundbreaking Gene Therapy for AML and MDS
How the Strategic Allocation Framework (SAF) Impacts the Future of CIRM’s Research Funding
At the California Institute for Regenerative Medicine (CIRM), our mission is to accelerate world class science to deliver transformative regenerative medicine treatments in an equitable manner to a diverse California and world. For nearly two decades, CIRM has been at the forefront of the regenerative medicine field, catalyzing significant scientific breakthroughs and developing therapies that … Continue reading How the Strategic Allocation Framework (SAF) Impacts the Future of CIRM’s Research Funding
CIRM $4 million awarded to support innovative Gene Therapy for Rare Heart Disorder
Image Source: American Heart Association Journals The California Institute for Regenerative Medicine (CIRM) recently awarded $4 million to support the development of a one-time gene therapy for desmoplakin gene variant arrhythmogenic cardiomyopathy (DSP ACM), a rare and life-threatening genetic disorder. This preclinical award to Deborah D. Ascheim, MD, and her team at Rejuvenate Bio are … Continue reading CIRM $4 million awarded to support innovative Gene Therapy for Rare Heart Disorder
CIRM awards $26 million to boost clinical trials for cancer, heart, and rare diseases
The California Institute for Regenerative Medicine (CIRM) is proud to announce the allocation of $26 million to support clinical research targeting a range of cancers, heart conditions, and rare diseases. This significant funding underscores CIRM’s commitment to advancing innovative stem cell and gene therapy-based treatments through all stages of clinical trial development. This latest round … Continue reading CIRM awards $26 million to boost clinical trials for cancer, heart, and rare diseases
Meet Our New CEO: Jonathan Thomas
We are thrilled to (re)introduce Jonathan Thomas (JT) as the new President and CEO of the California Institute for Regenerative Medicine (CIRM). You can check out the original press release here. We recently sat down with JT –who previously served as Chair of the Independent Citizens’ Oversight Committee (ICOC) as well as interim President and … Continue reading Meet Our New CEO: Jonathan Thomas
CIRM Welcomes Jonathan Thomas as New President and CEO
The California Institute for Regenerative Medicine (CIRM) is excited to announce the appointment of Jonathan “JT” Thomas, PhD, JD, as our new President and CEO. JT brings extensive experience and a deep commitment to our mission. Previously, he served as the Chair of the Independent Citizens' Oversight Committee (ICOC) for 12 years and, most recently, … Continue reading CIRM Welcomes Jonathan Thomas as New President and CEO
CIRM awards $25 million for discovery and clinical research, infrastructure programs
Stock image of a researcher The California Institute for Regenerative Medicine (CIRM) has recently approved awarding $25 million to fund multiple projects across discovery research, clinical research, and infrastructure programs.This funding will support 11 projects under CIRM's Foundation Awards Program, which aims to drive rigorous studies addressing critical basic knowledge gaps in the biology of … Continue reading CIRM awards $25 million for discovery and clinical research, infrastructure programs
CIRM approves $2.5 million to establish a Patient Support Program
Hataalii Tiisyatonii Begay (HT) participated in a CIRM-funded clinical trial at UCSF for Artemis-SCID, a condition that can be life-threatening or fatal. Photo courtesy Barbara Ries / UCSF. The California Institute for Regenerative Medicine (CIRM) funds innovative cell and gene therapy research and educational programs to advance regenerative medicine in the Golden State. Just as … Continue reading CIRM approves $2.5 million to establish a Patient Support Program
The Stem Cellar 